Kaitlyn D’Onofrio

DocwireNews

A new study found that combined nivolumab and bevacizumab may be an effective treatment strategy for women with relapsed <a href="https://www.docwirenews.com/docwire-pick/hem-onc-picks/harvard-research-links-ptsd-to-increased-risks-of-ovarian-cancer/">ovarian</a> <a href="https://www.docwirenews.com/docwire-pick/hem-onc-picks/should-cancer-patients-exercise/">cancer</a>.&ldquo;To date, single-agent programmed cell death 1 protein 1 (PD-1)/programmed death ligand 1 (PD-L1) immune checkpoint blockade has shown limited activity in recurrent epithelial ovarian cancer,&rdquo; wrote the researchers, whose study appeared in <a href="https://jamanetwork.com/journals/jamaoncology/article-abstract/2752504">JAMA Oncology</a>. &ldquo;Combination strategies of PD-1/PD-L1 inhibition with antiangiogenic therapy have the potential for synergistic activity through modulation of the microenvironment and represent a potential therapeutic opportunity in this disease.&rdquo;The trial was a single-arm, phase 2 study. Women with relapsed epithelial ovarian cancer were enrolled between Feb. 8, 2017, and Dec. 29, 2017, at two U.S.-based sites. Final analysis included 38 patients, all of whom had disease recurrence within 12 months of their most recent platinum-based therapy and had been given between one and three lines of previous therapy. The patients received intravenous nivolumab and intravenous bevacizumab once every two weeks. The main outcome measure was objective response rate (ORR) per the Response Evaluation Criteria in Solid Tumors 1.1. Other outcomes included ORR evaluation by platinum sensitivity, progression-free survival, safety outcomes, and the association of tumor PD-L1 with response to therapy.The mean (SD) age among the 38 patients was 63.0 (9.1) years; 18 patients had platinum-resistant and 20 had platinum-sensitive disease. Overall, 11 patients experienced a confirmed response to the combination treatment therapy (ORR, 28.9%; 95% exact binomial CI, 15.4%-45.9%); one additional response was unconfirmed. ORR varied between platinum-sensitive (40.0%) and platinum-resistant (16.7%) patients. Most (89.5%) patients sustained at least one treatment-related adverse event (AE), and nine (23.7%) patients experienced a treatment-related AE grade 3 or higher. Among the total cohort, median progression-free survival was 8.1 months. There were 36 histologic samples available for PD-L1 testing, of which 22 (61.1%) samples had a PD-L1 tumoral percentage less than 1, and 14 (38.9%) samples had a PD-L1 tumoral percentage of 1 or greater. Among patients with PD-L1 tumoral percentage less than 1, there were 10 responses, compared to responses in two patients among the PD-L1 tumoral percentage of 1 or greater group.&ldquo;The nivolumab with bevacizumab combination appeared to show activity in patients with relapsed ovarian cancer, with greater activity in the platinum-sensitive setting,&rdquo; the authors summarized. &ldquo;Alternative combinational strategies may be necessary in the platinum-resistant setting.&rdquo;

Jayme Locke, MD, MPH

Joel M. Topf, MD, FACP

The Promise of Xenotransplantation

NKF Spring Clinical Meetings 2025

Leah Lawrence

Real-World Data Backs Invasive DFS as Surrogate Endpoint for OS in EBC

HR Breast Cancer

Sacituzimab Govitecan Showed Modest Activity for CNS Metastases

Triple-Negative Breast Cancer

Latest News

Nivolumab Plus Bevacizumab Combo Effective in Relapsed Ovarian Cancer

Ovarian Cancer

A new study found that combined nivolumab and bevacizumab may be an effective treatment strategy for women with relapsed ovarian cancer. ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe